Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies
Authors: Sutar Jyoti , Jayal Priyanka , Mullick Ranajoy , Chaudhary Sangeeta , Kamble Prajakta , Bhowmick Shilpa , Kaginkar Snehal , Padwal Varsha , Devadiga Pratik , Neman Namrata , Kitchin Dale , Kaldine Haajira , Mkhize Nonhlanhla N. , Ndlovu Bongiwe , Gounder Kamini , Mukherjee Sohini , Shrivas Shweta , Sharma Neha , Prasad Chaman , Tewatia Sonia , Parihar Nainika , Kumar Naresh , Kasarpalkar Nandini , Singh Balwant , Mohapatra Shobha , Aquil Mohammad , Kumar C. Vishal , Dinesha Thongadi Ramesh , Srikrishnan Aylur Kailasom , Shastri Jayanthi , Agrawal Sachee , Gaikwad Sushma , Mondal Sayantani , Bandopadhyay Bhaswati , Guha Subhasish Kamal , Kale Dipesh , Biswas Debashis , Patil Dhanashree , Paranjape Ramesh S. , Mukhopadhyay Satyajit , Hema  , Das Ritika , Kondapi Anand , Bhor Vikrant , Deshpande Suprit , Sok Devin , Ndung’u Thumbi , Moore Penny L , Murugavel Kailapuri Gangatharan , Patel Vainav , Bhattacharya Jayanta 
Published: January 2025

Broadly neutralizing antibodies (bnAb) have been clinically proven to be an excellent choice for HIV-1 prevention. However, the relative effectiveness of best-in-class bnAbs against regionally relevant circulating HIV-1 forms is not clear. In the present study, we compared the degree of neutralization sensitivity of contemporary HIV-1 Indian clade C with that of South African origin. Phylogenetic analysis revealed that these clade C viruses continue to evolve distinctly from one another. Env-pseudotyped viruses prepared using contemporary HIV-1 clade Cenvgenes (N=115) obtained from nine geographically distinct sites in India (between 2020-2023) were found to be most sensitive to V3-directed bnAbs 10-1074 and BG18, and second generation CD4 binding site (CD4bs) directed bnAbs (VRC07, N6 and 1-18), however they were found to be significantly resistant to V1/V2 apex directed bnAbs. Moreover, we observed that the degree of sensitivity varied between contemporary Indian and South African clade C viruses. Differences in degree of neutralization susceptibility were associated with differences observed in key residues that form bnAb contact sites, gp120 loop lengths and the number of N-linked glycans in the V4 hypervariable region. Interestingly, the second generation CD4bs bnAbs (VRC07, N6, 1-18) showed neutralization of VRC01 and 3BNC117 resistant viruses but with 2-7-fold reduced potency compared to the VRC01 sensitive counterparts, likely due to the enrichment of resistance associated residues observed in loop D. Predictive analysis indicated that combination of BG18, N6 and PGDM1400 can provide over 95% neutralization coverage at 1μg/mL of contemporary India clade C, an observation found to be distinct to that reported for the Africa clade C viruses. Taken together, we found distinct neutralization patterns andenvsignatures associated with resistance to key bnAbs. Our study highlights that towards achieving clinical effectiveness, both the complementarity of bnAb classes and the regionally relevant HIV forms need to be considered.

Author summary

While the development of vaccines to prevent HIV infection remains a global priority, their potential effectiveness is limited by the extraordinarily diversified circulating forms of HIV-1. The prospect of best-in-class bnAbs as potential prevention option has been demonstrated in several studies including the Phase II Antibody Mediated Prevention (AMP) trial; however, to be broadly applicable, bnAbs will need to overcome the substantial variability of HIVenv. The present study highlights that the contemporary HIV-1 clade C viruses are evolving to be less sensitive to the best-in-class bnAbs and HIV-1 clade C that predominates in India and South Africa vary in their degree of susceptibility to best-in-class clinically relevant bnAbs. This indicates differences in the antigenic properties between globally circulating HIV-1 clade C at a population level. Overall, the outcome of this study highlights the need for periodic assessment of sequence and neutralization profiles of the circulating regionally relevant HIV-1 forms towards prioritizing the bnAb combination suitable for effective intervention.